Deletion Polymorphism of Angiotensin-Converting Enzyme Gene and Left Ventricular Hypertrophy in Southern Italian Patients  by Perticone, Francesco et al.
HYPERTENSION
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Objectives. This study sought to evaluate the possible associa-
tion of polymorphism of the angiotensin-converting enzyme
(ACE) gene with blood pressure and left ventricular mass index
(LVMI).
Background. The renin–angiotensin system seems to be in-
volved in the pathogenesis of essential hypertension. Moreover,
recent epidemiologic observations demonstrate that many sub-
jects with left ventricular hypertrophy have normal blood pressure
levels, suggesting that factors other than hemodynamic overload
may contribute to the hypertrophy.
Methods. The study included 140 untreated hypertensive out-
patients who underwent ambulatory blood pressure monitoring,
echocardiographic evaluation and analysis for insertion (I)/
deletion (D) polymorphism in intron 16 of the ACE gene by
polymerase chain reaction. Blood pressure was measured at 24 h,
and LVMI was calculated by the Devereux formula, in each
patient.
Results. Left ventricular mass index values (mean 6 SD) were
137 6 28 g/m2 in patients with the DD genotype, 125 6 27 g/m2 in
those with the ID genotype and 115 6 27 g/m2 in those with II
genotype. The frequencies of the DD, ID and II genotypes were
45.71% (n 5 64), 46.42% (n 5 65) and 7.85% (n 5 11), respec-
tively, and were in Hardy-Weinberg equilibrium. The strongest
association between left ventricular mass and DD genotype in our
cohort appeared to be an independent cardiovascular risk factor
(DD vs. ID: odds ratio [OR] 2.497, 95% confidence interval [CI]
interval 1.158 to 5.412, p < 0.05; DD vs. II: OR 6.577, 95% CI 1.169
to 28.580, p < 0.02).
Conclusions. Our data show that the LVMI was significantly
enhanced in patients with the DD genotype.
(J Am Coll Cardiol 1997;29:365–9)
q1997 by the American College of Cardiology
Epidemiologic studies show a continuous distribution of blood
pressure (BP) in the overall population (1). Studies of families
demonstrate that 20% to 40% of essential hypertension may
have a genetic basis (2). Several different candidate genes have
been considered in the pathogenesis of this disorder, in
agreement with the possibility that essential hypertension
might be a polygenic disease (3).
In particular, the renin–angiotensin system seems to be
involved in the pathophysiology of cardiovascular diseases by
regulating BP as well as fluid and electrolyte balance and may
have an important role in the pathogenesis of essential hyper-
tension. For these reasons, genes coding for components of
this system are attractive candidates for the investigation of the
genetic basic of essential hypertension.
The cloning of the angiotensin-converting enzyme (ACE)
gene has made it possible to identify a deletion (D)/insertion
(I) polymorphism that appears to be associated with different
levels of serum ACE activity (4–6). The genotype (DD)
associated with highest ACE levels has been identified as a
novel risk factor for myocardial infarction as well as dilated
and hypertrophic cardiomyopathy (7–9).
Left ventricular hypertrophy (LVH) is widely thought to be
a consequence of left ventricular pressure overload (7,8).
However, recent epidemiologic observations (10) demonstrate
that many subjects with LVH have normal BP levels, suggest-
ing that factors other than hemodynamic overload may con-
tribute to the hypertrophy (10).
The aim of our study was to explore, in a sample of
hypertensive subjects, a possible association between deletion
polymorphism in the gene coding for ACE and LVH identified
by echocardiography.
Methods
Study patients. The study included 140 outpatients at
Catanzaro University Hospital (69 men, 71 women; 28 to 65
years old, mean age [6SD] 53 6 11) with a well documented
history of chronic primary hypertension (time at onset 4 to 7
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months). All patients were white, and their families had been
living in Calabria for at least two generations. Causes of
secondary hypertension were excluded in all patients before
entering the protocol study. Physical examination and review
of medical history were performed before entrance into the
study. Each patient underwent standard electrocardiography,
routine chemical analyses and chest radiography. No patient
had a history of diabetes or hyperlipidemia.
The study was approved by the local ethical committee, and
all participants gave written informed consent for all proce-
dures.
Blood pressure measurements. Clinical BP measurements
were obtained in the morning between 8:00 AM and noon.
Blood pressure was measured three times with a mercury
sphygmomanometer. The mean of the last two measurements
was used.Hypertension was defined as systolic BP$160 mmHg
or diastolic BP $95 mm Hg, or both. All subjects had been
previously asked to refrain from smoking and drinking alco-
holic or caffeine-containing beverages during the previous 2 h.
Measurements were made by a physician with the subject
seated for at least 5 min.
Ambulatory BP monitoring was obtained using an A&D
TM 2420 recorder (model 7, Takeda, Tokyo, Japan), recently
validated in accordance with the protocol of the British Society
of Hypertension (11,12). The portable BP recorder uses a
dual-microphone system in a sphygmomanometer cuff to
record Korotkoff sounds. After being attached to the patients,
the unit was calibrated to within 5 mm Hg of simultaneous BP
measurements obtained with a mercury sphygmomanometer.
All ambulatory units were recalibrated after the 24-h registra-
tion was completed. Recordings were taken every 10 min
during the day (from 7:00 AM to 11:00 PM) and every 20 min
during the night (from 11:00 PM to 7:00 AM). The patients were
requested to observe these periods of rest and activity closely.
Mean values of heart rate and systolic, diastolic and mean
BP were calculated for each patient every hour. The results
obtained from each patient were averaged over the ambulatory
monitoring period throughout the entire 24-h period and
during the daytime and nighttime periods.
Echocardiograms. M-mode echocardiograms were ac-
quired with the patient in the partial left decubitus position,
using a Vingmed Sound CFM-800C (Horten, Norway) with an
annular phased-array 2.5-MHz transducer. Left ventricular
measurements were performed at end-diastole and end-
systole, according to the recommendations of the American
Society of Echocardiography (13). Left ventricular mass
(LVM) was calculated using the formula introduced by De-
vereux et al. (14): LVM 5 {1.04 3 [(IVSd 1 LVIDd 1 PWd)3
2 (LVIDd)3]} 2 13.6, where IVSd 5 interventricular septal
thickness at end-diastole; LVIDd 5 left ventricular internal
dimension at end-diastole; and PWd5 posterior wall thickness
at end-diastole. Individual values for LVM were indexed
by body surface area (LVMI) and considered normal at
,125 g/m2.
All echocardiographic examinations were performed by the
same experienced sonographer (C.C.). Echocardiographic
readings were made in random order by an investigator (M.T.)
who had no knowledge of BP levels and other clinical data.
Only frames with optimal visualization of interventricular septal
thickness, posterior wall thickness and left ventricular thick-
ness at end-diastole throughout the entire cardiac cycle were
considered for reading. The mean values from at least five
measurements of each variable in each patient were computed.
Detection of ACE polymorphism. DNA was partially puri-
fied from 6 ml of EDTA K3-treated whole blood (Vacutainer)
by means of a commercially available resin (InstaGene, Bio
Rad) according to the manufacturer’s instructions.
Twenty-nine milliliters of the partially purified material was
subjected to amplification by polymerase chain reaction (PCR)
according to previously published methods (15), with minor
modifications.
Briefly, reactions were performed with 10 pmol of each
primer:
Sense: oligo 59 CTGGAGACCACTCCCATCCTTTCT 39
Antisense: oligo 59GATGTGGCCATCACATTCGTCAGAT 39
in a final volume of 50 ml containing 3 mmol/liter MgCl2, 10
times concentrated PCR buffer (Perkin Elmer).
The DNA was amplified for 35 cycles with denaturation at
948C for 1 min, annealing at 588C for 1 min and extension at
728C for 2 min. The PCR products, separated by 1.5% agarose
gel electrophoresis, corresponded to a 190-base pair fragment
in the presence of the deletion and to a 490-base pair fragment
in the presence of the insertion.
Statistical analysis. Clinical and biologic data were com-
pared by analysis of variance. Qualitative data were compared
between groups by the chi-square test. Allele frequencies were
estimated by the gene-counting method, and the Hardy-
Weinberg equilibrium was verified by a chi-square test. The
independent influence of ACE genotypes on LVH was tested
by multivariate logistic regression analysis in autosomal dom-
inant, codominant and recessive modes (for the D allele).
Analysis included systolic and diastolic BP as continuous
variables. The calculation of odds ratio, providing an estimate
of the relative risk of LVH, was obtained in the three different
genotypes by an exact case-control test. Significant differences
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
BP 5 blood pressure
CI 5 confidence interval
D 5 deletion
I 5 insertion
LVH 5 left ventricular hypertrophy
LVM 5 left ventricular mass
LVMI 5 left ventricular mass index
OR 5 odds ratio
PCR 5 polymerase chain reaction
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were assumed to be present at p , 0.05. All group data are
reported as mean value 6 SD.
Results
Study patients. All 140 patients completed the protocol
study. Demographic and humoral characteristics are summa-
rized in Table 1. The groups did not differ significantly with
regard to systolic and diastolic BP, heart rate, body mass index,
hematocrit and total and high density lipoprotein cholesterol.
Frequencies of alleles and genotypes. Among the 140
hypertensive subjects studied, the I and D alleles had frequen-
cies of 31.1% and 68.9%, respectively, similar to frequencies
observed in a normal cohort from the same area (16). The
distribution of the DD, ID and II genotypes was 45.7% (n 5
64), 46.4% (n 5 65) and 7.8% (n 5 11), respectively, and were
in Hardy-Weinberg equilibrium.
Association between genotype and BP. The clinic and
ambulatory BP mean values were not significantly different in
our three genotypes. Systolic and diastolic clinical BP values
were 164/97 6 20/8 mm Hg and 158/102 6 16/6 mm Hg in the
DD and II homozygous groups, respectively, and 161/98 6
22/11 in the ID group, but these differences were not statisti-
cally significant (Table 2).
Associations between genotype and LVH. The LVMI val-
ues obtained in our cohort were 137 6 28 g/m2 for the DD
genotype, 125 6 27 g/m2 for the ID genotype and 115 6
27 g/m2 for the II genotype. Multivariate logistic regression
analysis of ACE genotypes showed no correlation of LVM to
BP levels. Comparison of the three groups revealed that DD
genotype was associated with a significantly increased LVM, as
detected by echocardiography (Fig. 1): 38 (59.4% [18 men, 20
women]) patients with the DD genotype, 24 (36.9% [15 men, 9
women]) with the ID genotype and 2 women (22.2%) with the
II genotype had an LVMI .125 g/m2 (p , 0.02, DD vs. ID;
p , 0.05, DD vs. II; p 5 NS, ID vs. II). The 2 3 3 analysis of
variance test showed that LVM was not affected by gender
itself, but its interaction with ACE genotype was able to
influence cardiac mass size significantly (p , 0.005).
The association between LVM and ACE genotype in our
cohort appeared to be an independent cardiovascular risk
factor and was strongest for LVM and the DD genotype (DD
vs. ID: odds ratio [OR] 2.497, 95% confidence interval [CI]
Table 1. Clinical Characteristics of 140 Hypertensive Study Patients
DD Group
(n 5 64)
ID Group
(n 5 65)
II Group
(n 5 11)
Age (yr) 54 6 3 52 6 4 53 6 2
Male/female 30/34 32/33 6/5
Body mass index (kg/m2) 25.3 6 1.2 24.9 6 1.3 25.1 6 1.6
Heart rate (beats/min) 75 6 3 77 6 3 73 6 1
Total cholesterol (mmol/liter) 4.5 6 0.3 4.5 6 0.2 4.4 6 0.2
HDL cholesterol (mmol/liter) 1.1 6 0.1 1.0 6 0.2 1.1 6 0.2
Glycemia (mmol/liter) 5.2 6 0.4 4.9 6 0.5 5.0 6 0.5
Potassium (mmol/liter) 4.0 6 0.1 3.9 6 0.2 4.1 6 0.2
Hematocrit (%) 40 6 2 41 6 2 40 6 3
Data presented are mean value 6 SD or number of patients. D 5 deletion; HDL 5 high density lipoprotein; I 5
insertion.
Table 2. Clinical and Ambulatory Blood Pressure Values for the Three Genotypes
DD Group
(n 5 64)
ID Group
(n 5 65)
II Group
(n 5 11)
p
Value
Clinical BP (mm Hg)
Systolic 164 6 20 161 6 22 158 6 16 0.563
Diastolic 97 6 8 98 6 11 102 6 6 0.266
24-h BP (mm Hg)
Systolic 150 6 18 149 6 13 143 6 10 0.379
Diastolic 89 6 11 90 6 9 87 6 5 0.606
Daytime BP (mm Hg)
Systolic 154 6 19 152 6 13 147 6 10 0.379
Diastolic 91 6 11 92 6 9 90 6 7 0.753
Nighttime BP (mg)
Systolic 138 6 19 138 6 17 129 6 16 0.280
Diastolic 80 6 13 82 6 9 77 6 6 0.294
Data presented are mean value 6 SD. BP 5 blood pressure; other abbreviations as in Table 1.
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1.158 to 5.412, p , 0.05; DD vs. II: OR 6.577, 95% CI 1.169 to
28.580, p , 0.02).
Discussion
Deletion polymorphism in the gene coding for ACE has
been associated with an increased risk for coronary artery
disease (17), LVH (evaluated by comparison with electrocar-
diographic results in a normal population) (18), hyperglycemia
(16) and dilated cardiomyopathy (8). We showed that clinical
and ambulatory BP values were not significantly different
between the three genotype groups. In contrast, deletion
polymorphism in the ACE gene is associated with an increased
risk of echocardiographic LVH in a group of previously
untreated hypertensive patients.
Left ventricular mass and I/D polymorphism. Echocardi-
ography is an extremely accurate method that allows measure-
ment of LVM (19). Patients homozygous for deletion (DD)
were characterized by a significantly elevated LVM and a
higher relative risk of developing LVH (LVMI .125 g/m2),
than patients heterozygous (ID) and homozygous (II) for
insertion. The present data are in agreement with previous
reports (18,20) suggesting that homozygosity for the D allele
may represent a risk factor for LVH. In contrast, our data seem
to be in conflict with the results of other published studies
(21,22) that found no evidence of association of echocardio-
graphically estimated LVH and D/I polymorphism. However,
this discrepancy is only apparent because our patients were all
hypertensive and previously untreated, whereas Kupari et al.
(21) and Lindpaintner et al. (22) included normotensive and
treated hypertensive patients and subjects free of clinical heart
disease. Finally, according to Lechin et al. (23), who demon-
strated that homozygosity for the D allele increases the risk of
hypertrophy in patients with hypertrophic cardiomyopathy, we
postulate that ACE genotypes play a role in modulating the
hypertrophic response of the myocardium to stress.
Angiotensin-converting enzyme activity and ventricular hy-
pertrophy. It has been reported by several groups (4–6) that
deletion polymorphism is associated with elevated serum ACE
activity. The ACE has several functions related and unrelated
to the renin-angiotensin system. In particular, the ACE has
been demonstrated to be involved in the inactivation of both
bradykinin, a potent vasodilator (24), and AcSDKP, a negative
regulator of hematopoietic stem cell proliferation (25).
The main function of ACE is considered to be the proteo-
lytic activation of angiotensin I to angiotensin II. The latter has
been demonstrated to be a growth factor for vascular smooth
muscle cells (26) and a stimulator of type I and type III
collagen synthesis in myocardial interstitial cells (27,28).
Thus, patients homozygous for deletion in the ACE gene,
characterized by elevated serum ACE activity, may develop
LVH because of myocytic hypertrophy secondary to medial
thickening of resistance vessels, as well interstitial accumula-
tion of collagen, actively synthesized by cardiac fibroblasts.
Angiotensin II could be directly responsible for the hyper-
trophy of the cardiac ventricular myocyte. However, this
suggestive hypothesis is very difficult to test because ventricular
cell lines are not available, and in vivo studies are difficult to
perform with current technology.
Conclusions. The present study included new, previously
untreated hypertensive patients. It is unlikely that LVH could
result from pressure overload, given the short duration of the
underlying hypertensive disease. It is thus possible that ele-
vated serum ACE activity in patients homozygous for deletion
(DD) might result in LVH because of nonmyocytic cell growth,
a mechanism that might be responsible for other molecular
cardiac diseases when associated with different genetic abnor-
malities.
We thank Fabiola Pugliese, MD and Raffaele Maio, MD for help in the
collection of clinical and ambulatory blood pressure data.
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